For patients unable to effectively control their blood pressure with lifestyle changes and medication therapy, a new class of interventional products have been under development this past decade as an investigational treatment of hypertension using a procedure called renal denervation. This investigational procedure ablates the sympathetic nerves in order to reduce their overactivity. Most recently, data from three sham-controlled renal denervation trials using second-generation technology showed similar consistent decreases in blood pressure.⁴ The 2023 ESH guidelines acknowledge the safety of RDN based on the available data and that RDN represents a treatment option that is additive or alternative to increasing medication in patients with uncontrolled resistant hypertension who do not have a secondary cause of hypertension.⁵  These guidelines state that selection of patients to whom RDN is offered should be done in a shared decision-making process after objective and complete patient information. These guidelines also state that RDN should only be performed in experienced specialized centers to guarantee appropriate selection of eligible patients and completeness of the denervation procedure.